Tilray, a Canadian pot company, announced on Thursday that the US government had granted it permission to import high-quality CBD products into the US for research purposes. The School of Medicine at New York University will partner with Tilray to conduct two clinical trials using the imported CBD products.
NYU plans to study the effect of CBD on patients who suffer from alcohol use disorder. The other clinical trial will focus on patients with post-traumatic stress disorder (PTSD). In order to do this research, NYU needed high-quality marijuana raw materials, and Tilray stepped in to address that need. The CBD will be in capsule form.
The research comes amidst widespread beliefs that CBD products can be viable alternatives to the traditional medicines used to treat or manage different conditions. However, there has been a shortage of scientific studies to confirm that CBD works for different ailments. The studies at NYU are just some of the ongoing trials aimed at getting the scientific data needed to give the public and policymakers a sound basis for the decisions that they make.
The planned trials at NYU will be randomized double-blind clinical trials. This type of study design is the gold standard in the scientific community for any findings to be regarded as credible. NYU therefore has opted for the very best way in which to do its research.
The timing of the research also deserves some attention. In the past, industrial hemp was illegal, just as marijuana still is. Consequently, scientists found it hard to research the benefits of the different marijuana compounds since the U.S. federal government established a prohibitive bureaucracy that the scientific community had to navigate before they could get approval for their trials to begin.
Now that hemp is legal across the U.S., the scientific community is using the current favorable climate to use cannabinoids from hemp to study how different compounds can be beneficial or otherwise to people.
New York University isn’t the first research institution to get approval to import marijuana compounds. Other entities, such as the University of California San Diego and the Ultimate Fighting Championship Performance Institute have also partnered with Canadian marijuana companies to import research-grade cannabis products which aren’t locally available as yet.
Meanwhile, pressure is mounting on the U.S. federal government to license more cultivators and manufacturers of research-grade marijuana products to supplement what is available from the University of Mississippi. It isn’t clear when the DEA will act upon the applications it received in this regard.
Industry watchers are convinced that CBD industry players like Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) and TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) will not be content until the U.S. fully modifies its policies to allow the industry to thrive.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com